Login to Your Account

U.S. Patent Disclosures

Tuesday, August 16, 2011
• Silence Therapeutics plc, of London, received a notice of allowance for a patent directed to the technology involved in AtuPLEX, one of its small interfering RNA delivery systems. It specifically relates to AtuFect, the lipid that serves as the basis for the AtuPLEX delivery system, and covers the system incorporated in lead compound Atu027 and other RNAi candidates.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription